Drugs / VLX-1005
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05325346 | Mar → Apr 2022 | heparin-induced thrombocytopenia | Veralox Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04783545 | Mar 2021 → Jan 2022 | — | Veralox Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05785819 | Sep 2023 → Nov 2025 | heparin-induced thrombocytopenia, thrombocytopenia due to immune destruction | Veralox Therapeutics | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VLX-1005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05325346 ↗ |
| Known as | ML-355 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3113165 ↗ |
| Action | Inhibit | “VLX-1005 is a drug that blocks the 12-lipoxygenase (12-LOX) pathway” NCT05785819 ↗ |
| Modality | Small molecule | — CHEMBL3113165 ↗ |
| Route | Intravenous | “following intravenous (IV) administration” NCT04783545 ↗ |